ECSP088593A - 5-(arilsulfonil)-pirazolopiperidinas - Google Patents

5-(arilsulfonil)-pirazolopiperidinas

Info

Publication number
ECSP088593A
ECSP088593A EC2008008593A ECSP088593A ECSP088593A EC SP088593 A ECSP088593 A EC SP088593A EC 2008008593 A EC2008008593 A EC 2008008593A EC SP088593 A ECSP088593 A EC SP088593A EC SP088593 A ECSP088593 A EC SP088593A
Authority
EC
Ecuador
Prior art keywords
formula
compounds
pirazolopiperidins
arilsulfonil
alzheimer
Prior art date
Application number
EC2008008593A
Other languages
English (en)
Inventor
Andrei Konradi
Christopher M Semko
Ying-Zi Xu
Jenifer Smith
Xiacong Michael Ye
Albert W Garofalo
Jacek J Jagodzinski
Original Assignee
Elan Pharm Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Elan Pharm Inc filed Critical Elan Pharm Inc
Publication of ECSP088593A publication Critical patent/ECSP088593A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/92—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with a hetero atom directly attached to the ring nitrogen atom
    • C07D211/96—Sulfur atom
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Veterinary Medicine (AREA)
  • Biomedical Technology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

La invención proporciona compuestos de sulfonamido N-cíclicos de la Fórmula (I) en donde A, B, R1, R1a, R2, R2a, R3 y R3a son como se describen en la especificación. Los compuestos de la fórmula (I) son útiles en el tratamiento o prevención de los trastornos cognoscitivos, tal como enfermedad de Alzheimer. La invención también abarca composiciones farmacéuticas que comprenden los compuestos de la Fórmula (I), métodos para preparar los compuestos de la Fórmula (I), y métodos para el tratamiento de trastornos cognoscitivos, tal como enfermedad de Alzheimer
EC2008008593A 2005-12-01 2008-07-01 5-(arilsulfonil)-pirazolopiperidinas ECSP088593A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US74136605P 2005-12-01 2005-12-01

Publications (1)

Publication Number Publication Date
ECSP088593A true ECSP088593A (es) 2008-08-29

Family

ID=38092841

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2008008593A ECSP088593A (es) 2005-12-01 2008-07-01 5-(arilsulfonil)-pirazolopiperidinas

Country Status (18)

Country Link
US (2) US7732609B2 (es)
EP (1) EP1957458A2 (es)
JP (1) JP2009518301A (es)
KR (1) KR20080073359A (es)
CN (1) CN101370776A (es)
AR (1) AR057959A1 (es)
AU (1) AU2006320423B2 (es)
BR (1) BRPI0619633A2 (es)
CA (1) CA2632227A1 (es)
EA (1) EA014906B1 (es)
EC (1) ECSP088593A (es)
IL (1) IL190608A0 (es)
MA (1) MA30089B1 (es)
MY (1) MY149422A (es)
NZ (1) NZ568109A (es)
PE (1) PE20071090A1 (es)
TW (1) TW200736255A (es)
WO (1) WO2007064914A2 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20100378T1 (hr) * 2006-05-31 2010-08-31 Galapagos N.V. Spojevi triazolopirazina učinkoviti za tretman degenerativnih i upalnih bolesti
MX2009012525A (es) * 2007-05-25 2009-12-09 Elan Pharm Inc Pirazol-pirrolidinas como inhibidores de gamma secretasa.
EP2271625B1 (en) 2008-04-01 2012-09-12 Abbott GmbH & Co. KG Tetrahydroisoquinolines, pharmaceutical compositions containing them, and their use in therapy
TW201038569A (en) * 2009-02-16 2010-11-01 Abbott Gmbh & Co Kg Heterocyclic compounds, pharmaceutical compositions containing them, and their use in therapy
AR075442A1 (es) 2009-02-16 2011-03-30 Abbott Gmbh & Co Kg Derivados de aminotetralina, composiciones farmaceuticas que las contienen y sus usos en terapia
US20110034691A1 (en) * 2009-03-25 2011-02-10 Elan Pharmaceuticals, Inc. Process for the Production of Fused, Tricyclic Sulfonamides
US8883839B2 (en) 2010-08-13 2014-11-11 Abbott Laboratories Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US8877794B2 (en) 2010-08-13 2014-11-04 Abbott Laboratories Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9045459B2 (en) 2010-08-13 2015-06-02 AbbVie Deutschland GmbH & Co. KG Phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US8846743B2 (en) 2010-08-13 2014-09-30 Abbott Laboratories Aminoindane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9051280B2 (en) 2010-08-13 2015-06-09 AbbVie Deutschland GmbH & Co. KG Tetraline and indane derivatives, pharmaceutical compositions containing them, and their use in therapy
US9309200B2 (en) 2011-05-12 2016-04-12 AbbVie Deutschland GmbH & Co. KG Benzazepine derivatives, pharmaceutical compositions containing them, and their use in therapy
MX2014001457A (es) 2011-08-05 2014-08-21 Abbvie Deutschland Derivados de aminocromano, de aminotiocromano y de amino-1,2,3,4-tetrahidroquinolina composiciones farmaceuticas que los contienen, y su uso en terapia.
WO2013072520A1 (en) 2011-11-18 2013-05-23 AbbVie Deutschland GmbH & Co. KG N-substituted aminobenzocycloheptene, aminotetraline, aminoindane and phenalkylamine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9365512B2 (en) 2012-02-13 2016-06-14 AbbVie Deutschland GmbH & Co. KG Isoindoline derivatives, pharmaceutical compositions containing them, and their use in therapy
US9656955B2 (en) 2013-03-15 2017-05-23 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
US9650334B2 (en) 2013-03-15 2017-05-16 Abbvie Inc. Pyrrolidine derivatives, pharmaceutical compositions containing them, and their use in therapy
JP2016533375A (ja) 2013-10-17 2016-10-27 アッヴィ・ドイチュラント・ゲー・エム・ベー・ハー・ウント・コー・カー・ゲー アミノテトラリン誘導体およびアミノインダン誘導体、これらを含有する医薬組成物、および治療におけるこれらの使用
CA2924689A1 (en) 2013-10-17 2015-04-23 AbbVie Deutschland GmbH & Co. KG Aminochromane, aminothiochromane and amino-1,2,3,4-tetrahydroquinoline derivatives, pharmaceutical compositions containing them, and their use in therapy
CN104059063A (zh) * 2014-04-03 2014-09-24 丽水绿氟科技有限公司 7,7-二氟-4,5,6,7-四氢吡唑并[4,3-c]吡啶及其衍生物的制备方法
CR20200464A (es) 2018-03-08 2021-04-14 Incyte Corp Compuestos diólicos de aminopirazina como inhibidores de pi3k-y
WO2020010003A1 (en) 2018-07-02 2020-01-09 Incyte Corporation AMINOPYRAZINE DERIVATIVES AS PI3K-γ INHIBITORS

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL319758A1 (en) 1994-10-20 1997-08-18 Pfizer Bicyclic tetrahydropyrasole pyridines and their application as medicines
CA2416527C (en) * 2000-08-10 2009-12-22 Pharmacia Italia S.P.A. Bicyclo-pyrazoles active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
US7375115B2 (en) * 2001-10-09 2008-05-20 Kyorin Pharmaceutical Co., Ltd. 4-(2-furoyl) aminopiperidines, intermediates in synthesizing the same, process for producing the same and medicinal use of the same
AU2003292724A1 (en) * 2002-12-27 2004-07-29 Japan Tobacco Inc. Fused n-containing heterocyclic compounds and medicinal use thereof
WO2005113542A2 (en) * 2004-05-20 2005-12-01 Elan Pharmaceuticals, Inc. N-cyclic sulfonamido inhibitors of gamma secretase
US20060089378A1 (en) * 2004-10-27 2006-04-27 Mingde Xia Tetrahydro-pyridinyl pyrazole cannabinoid modulators
DE102005002500A1 (de) * 2005-01-19 2006-07-27 Sanofi-Aventis Deutschland Gmbh Tetrahydrofuranderivate als Inhibitoren von Matrix-Metalloproteinasen
EP1863810A4 (en) * 2005-03-22 2010-03-31 Astrazeneca Ab NEW TETRAHYDRO-1H-PYRIDO [4,3-B] INDOLDERIVATE AS CB1 'RECEPTOR LIGANDS
DE102005016170A1 (de) * 2005-04-07 2006-10-12 Grünenthal GmbH 4,5,6,7- Tetrahydro-isoxazolo(4,5c)pyridin-Verbindungen und deren Verwendung zur Herstellung von Arzneimitteln
JP2009504773A (ja) * 2005-08-19 2009-02-05 エラン ファーマシューティカルズ，インコーポレイテッド ガンマセクレターゼの架橋ｎ−二環式スルホンアミド阻害剤

Also Published As

Publication number Publication date
PE20071090A1 (es) 2007-10-24
MY149422A (en) 2013-08-30
IL190608A0 (en) 2008-11-03
EA014906B1 (ru) 2011-02-28
WO2007064914A2 (en) 2007-06-07
US20070155753A1 (en) 2007-07-05
AR057959A1 (es) 2007-12-26
WO2007064914A8 (en) 2008-05-15
JP2009518301A (ja) 2009-05-07
CN101370776A (zh) 2009-02-18
AU2006320423B2 (en) 2012-06-21
US20100267747A1 (en) 2010-10-21
CA2632227A1 (en) 2007-06-07
US7732609B2 (en) 2010-06-08
TW200736255A (en) 2007-10-01
MA30089B1 (fr) 2008-12-01
EA200801481A1 (ru) 2009-02-27
EP1957458A2 (en) 2008-08-20
AU2006320423A1 (en) 2007-06-07
WO2007064914A3 (en) 2007-12-27
KR20080073359A (ko) 2008-08-08
BRPI0619633A2 (pt) 2011-10-04
NZ568109A (en) 2011-07-29

Similar Documents

Publication Publication Date Title
UY30377A1 (es) Inhibidores triciclicos fusionados de sulfonamida de gama-secretasa
TW200736255A (en) 5-(Substituted)-pyrazolopiperidines
PA8680701A1 (es) Derivados de oxindol
PA8593101A1 (es) Composiciones para el tratamiento de crecimiento celular anormal
DOP2006000169A (es) Inhibidores espiropiperidina de beta-secretasa para el tratamiento de la enfermedad de alzheimer
UY28885A1 (es) 4-fenilamino-quinazolin-6-il-amidas referencia cruzada a solicitud(es) relacionada(s)
CU20090184A7 (es) Compuestos amino-heterocíclicos
DOP2002000422A (es) Agentes antibacterianos.
CL2009000349A1 (es) Compuestos derivados de 4,5-dihidro-oxazol-2-ilamina; procedimiento de preparacion; composicion farmaceutica; y su uso para el tratamiento de la enfermedad de alzheimer.
CR9459A (es) Derivados benzodioxano y benzodioxolano y usos de los mismos
TN2009000180A1 (en) NOVEL 1,4-BENZOTHIEPIN-l,1-DIOXIDE DERIVATIVES WHICH ARE SUBSTITUTED WITH BENZYL GROUPS, METHOD FOR PRODUCING DRUGS CONTAINING SAID COMPOUNDS AND USE THEREOF
CR9078A (es) Derivado de bencimidazol ariloxi-sustituidos
BRPI0418181A (pt) emprego de 2-aminotetralinas substituìdas para prevenção do tratamento de morbus parkinson
MX2009012525A (es) Pirazol-pirrolidinas como inhibidores de gamma secretasa.
CL2008001820A1 (es) Compuestos derivados de aril-isoxasol-imidazol; procedimiento de preparacion; composicion farmaceutica que los contiene; y uso en la preparacion de medicamentos utiles en el tratamiento de trastornos cognitivos y enfermedades relacionadas con alzheimer.
UY28861A1 (es) Nuevas combinaciones farmacologicas para el tratamiento de enfermedades de las vias respiratorias
PA8568101A1 (es) Indolil-urea derivados de tienopiridinas utiles como agentes antiangiogenicos, y procedimientos para su uso
UY27980A1 (es) Indoles 2,7-sustituidos
GT200600161A (es) Nuevas combinaciones terapeuticas para el tratamiento o la prevencion de los trastornos psicoticos
PA8589801A1 (es) Aminoalcoxiindoles
GT200800066A (es) Derivados de 9-cloro-15-deoxiprostaglandina, procedimiento para su preparacion y su uso como medicamento.
HN2011000404A (es) Derivados de enfumafungina y composicion comprendiendo los mismos
UY29394A1 (es) Derivados sustituidos de n-(5-(2-propilamino.1.hidroxietil)-2-hdroxifenil) metano sulfonamida, composiciones farmacéuticas que lo contienen y aplicaciónes.
DE602006018359D1 (de) Heterocyclische derivate, deren herstellung und therapeutische verwendung
DOP2002000386A (es) Agentes antibacterianos